Constellation Energy (NASDAQ:CEG) shares fell 7% on Tuesday after management released full-year 2026 guidance that, at its midpoint, came in below consensus analyst expectations.
The company set adjusted operating earnings per share for fiscal 2026 in a range of $11 to $12. That midpoint undercut the average analyst estimate of $11.72, prompting investor disappointment despite a set of aggressive capital deployment and shareholder-return measures unveiled alongside the guidance.
Among actions disclosed, Constellation plans to commit $3.9 billion to growth capital expenditures and has increased its share buyback authorization to $5 billion. In addition, management projected base EPS growth exceeding 20% from 2026 through 2029.
Analyst reaction was mixed. Nicholas Campanella of Barclays, who retains an overweight rating and a $356 price target on the stock, characterized the outlook as mixed. He noted that nuclear contracting work is moving forward but that the EPS outlook fell short of expectations even as the company maintained the accretion guidance associated with its Calpine acquisition.
"The company has been clear in previous communication that the CPN accretion was a well vetted number, but investors have continued to see upside to CEG/CEG pro forma and expectations we think were high," Campanella commented.
The guidance was provided as Constellation continues integrating the Calpine acquisition and advancing its nuclear energy contracting business. Management's plans combine heavy near-term capital expenditure with an expanded buyback program and a multi-year EPS growth target.
Investors reacted primarily to the variance between the guidance midpoint and the street estimate, while the company emphasized its longer-term growth trajectory and the expected contribution from recent strategic initiatives.
Contextual note - The company's statements focused on fiscal 2026 adjusted operating EPS, planned capital investments, share-repurchase authorization, multi-year base EPS growth targets, progress in nuclear contracting, and ongoing integration of the Calpine acquisition. Market reaction centered on the guidance miss reflected at the midpoint.